The Bob Harrington Show - Episode 16: PLATO, ticagrelor, and platelet inhibition: Insight from Lars Wallentin

Summary: With two months perspective since the simultaneous publication of PLATO trial results at ESC 2009 and in NEJM, Lars Wallentin joins the show for an insightful review of the results, context, and importance of PLATO, specifically: § An explanation of why ticagrelor is a different type of platelet inhibitor § Top line results of PLATO § Insight into the mortality finding § A review of the invasively managed cohort data presented by Chris Cannon at TCT 2009 § Discussion of the effect on stent thrombosis § The "North American issue" and what might explain the anomalous North American results compared to those of the rest of the world § Background on the late-breaker—addressing patients with STEMI—at AHA 2009 that will be presented by Gabriel Steg What are your thoughts? Join in by commenting below.